報價延遲最少15分鐘:2025/06/02 21:43 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.49 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.78/-3.33
|
|
企業價值
114.29M
|
| 資產負債 |
|
每股賬面淨值
4.32
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 21:43 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role. |